LifeMD tirzepatide review
Advertised at $75, billed at $149. Position 0 of 18 on our board.
Updated 2026-09-18
DISCLOSURE — Coreage Rx pays this desk a commission when a reader signs up through our link. It buys no ranking, no score and no deletions. Method: how we rate. Full terms: disclosure.
LifeMD charges $149 a month for the programme and no medication comes with it. Whether that is cheap or expensive depends entirely on your insurance card.
It is $75 for the first month, then $149, with an annual plan holding nearer $75. The fee buys clinical care and administrative work — prior authorisations, appeals, keeping a prescription live.
The numbers
| LifeMD · tirzepatide | |
|---|---|
| Advertised | $75/mo |
| Membership | None |
| Billed | $149/mo |
| Advertised-to-billed gap | +$74/mo |
| Per year | $1,788 |
| Board position | 0 of 18, cheapest first |
Programme fee only. Branded medication cost sits on top unless insurance covers it.
Where the gap is
No concealed fee. The gap is expectation: people read "as low as $75 a month" as a medication price. It is not. If your insurer declines, you pay the fee and buy the drug separately at market rate.
Against the board
About $1,788 a year in fees, plus medication where uncovered. Insured, it can undercut everything on the board. Uninsured, Coreage Rx at $2,388 covers both the care and the drug for less than LifeMD’s fee plus a prescription.
| Programme | Advertised | Billed | Gap | Vs board floor |
|---|---|---|---|---|
| Coreage Rx | $149 | $199 | +$50 | +$74/mo |
| Trimi | $125 | $125 | none | — |
| Ozari Health | $125 | $125 | none | — |
| Fifty 410 | $133 | $133 | none | +$8/mo |
| PlexusDx | $129 | $189 | +$60 | +$64/mo |
| Ivím Health | $199 | $199 | none | +$74/mo |
| Zealthy | $216 | $216 | none | +$91/mo |
| Hims & Hers | $199 | $238 | +$39 | +$113/mo |
How the programme works
Physician-led telehealth group with a weight-management programme built around insurance coordination and branded prescriptions.
Verified facts
- GLP-1 injection programme listed at $75 first month, then $149/month.
- Annual plan advertised as low as $75/month.
- Programme fee does not include medication when medication is branded and billed to insurance.
- Markets insurance coordination that can reduce semaglutide cost to roughly $25/month where coverage applies.
Checked 2026-09-18. This market re-prices without notice — anything older than a month is a starting point, not a quote.
For it
- Genuine clinician oversight with a physician-led model.
- Insurance work is a core part of the service, not an afterthought.
- Annual plan meaningfully reduces the programme fee.
Against it
- The programme fee buys care, not medication.
- Cash-pay outcomes are far less attractive than insured ones.
Read this bit. If your insurer declines, the $149/month programme fee still applies and the medication is extra.
Score
3.5 out of 5 on our rubric, which is fixed before assessment and published on how we rate.
| Criterion | Weight | Score |
|---|---|---|
| True monthly cost | 30% | 3 / 5 |
| Price honesty | 20% | 3.3 / 5 |
| Clinical support | 20% | 4 / 5 |
| Pharmacy sourcing | 15% | 4.2 / 5 |
| Cancelling | 15% | 3.4 / 5 |
Verdict
Physician-led and genuinely good at insurance work. One phone call to your insurer tells you whether it is worth it.
More from the desk
- Coreage Rx tirzepatide review
Advertised at $149, billed at $199. Position 1 of 18 on our board.
- Trimi tirzepatide review
Advertised at $125 and billed at $125 — no gap. Position 2 of 18 on our board.
- Ozari Health tirzepatide review
Advertised at $125 and billed at $125 — no gap. Position 3 of 18 on our board.
- Cheapest right now
Every programme sorted on what it bills, not what it advertises. Floor: $199/mo tirzepatide, $149/mo semaglutide.
- Six fee traps
Every advertised-to-billed gap on our board comes from one of these six structures. Learn them and you can read any of these sites in ninety seconds.
- Where the traps are
The biggest advertised-to-billed gaps on our board, and the programmes charging most for the same category of medication.